Kinase Inhibitors

Kinase Inhibitor

Carcinoma, Non-Small-Cell Lung

<section class="Section" data-sectioncode="34089-3"><a name="S11"></a><a name="section-9"></a><p></p><h1>11 DESCRIPTION</h1><p class="First">ALECENSA (alectinib) is a kinase inhibitor for oral administration. The molecular formula for alectinib is C<span class="Sub">30</span>H<span class="Sub">34</span>N<span class="Sub">4</span>O<span class="Sub">2</span> ∙ HCl. The molecular weight is 482.62 g/mol (free base form) and 519.08 g/mol (hydrochloride salt). Alectinib is described chemically as 9-ethyl-6, 6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-6, 11-dihydro-5<span class="Italics">H</span>-benzo[<span class="Italics">b</span>]carbazole-3-carbonitrile hydrochloride. The chemical structure of alectinib is shown below: </p><div class="Figure"><img alt="Chemical Structure" src="alecensa-01.jpg"/></div><p>Alectinib HCl is a white to yellow white powder or powder with lumps with a pKa of 7.05 (base). </p><p>ALECENSA is supplied as hard capsules containing 150 mg of alectinib (equivalent to 161.33 mg alectinib HCl) and the following inactive ingredients: lactose monohydrate, hydroxypropylcellulose, sodium lauryl sulfate, magnesium stearate, and carboxymethylcellulose calcium. The capsule shell contains hypromellose, carrageenan, potassium chloride, titanium dioxide, corn starch, and carnauba wax. The printing ink contains red iron oxide (E172), yellow iron oxide (E172), FD&amp;C Blue No. 2 aluminum lake (E132), carnauba wax, white shellac, and glyceryl monooleate.</p></section>

ALECENSA

alectinib

alectinib 150 MG Oral Capsule

Alecensa

alectinib 150 MG Oral Capsule [Alecensa]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Alecensa is a medication that belongs to the class of tyrosine kinase inhibitors and can be used to treat non-small cell lung cancer (NSCLC) caused by a mutation in the ALK gene. It is taken orally twice a day but may cause some severe side effects like pneumonitis, kidney disease, and bradycardia that may lead to discontinuation or dosage reduction.

Alecensa is FDA approved for ALK+ metastatic non-small cell lung cancer. 

Report Adverse Event

Prescribing Information - English

Prescribing Information - Spanish

Prescribing Information - Chinese

Medication Guide 

Submit MSL Request 

Reimbursement Information

Pharmacy List

How To Order Alecensa

Billing and Coding Guide 

Coverage Authorization Request 

Coverage Authorization Appeals

Letter of Medical Necessity 

Prescriber Service & Patient Consent Form 

Prescriber Service Form - Online Portal 

Patient Consent Form 

Patient Consent Form - Spanish 

My Patient Solutions - HCP Portal (for managing service requests)

Enroll in Patient Savings Program

Genentech Patient Foundation Application Form - Prescriber Form 

Alecensa Sure Start Program 

HCPs Register for Latest Updates

Other HCP Resources: Access

Other HCP Resources: Financial Assistance Options 

Other HCP Resources: Downloads 

About Alecensa

Side Effects

Taking Alecensa

Doctor Discussion Guide 

Patient Stories 

Alecensa Staying Positive Support Program

Real Talk about ALK+ mNSCLC 

Patient Resources 

Patient Education Brochure - English

Patient Education Brochure - Spanish

Patient Education Brochure - Chinese

Instructions For Use: NSCLC